Chinese NMPA approves Innovent and IASO Bio’s myeloma therapy
China has granted approval for Innovent Biologics and IASO Bio Fucaso for treating relapsed or refractory multiple myeloma (RRMM) in adults.
China has granted approval for Innovent Biologics and IASO Bio Fucaso for treating relapsed or refractory multiple myeloma (RRMM) in adults.
What's Your Reaction?
